Martin et al. (104) |
CMV homolog selection and epitope prediction (HLA-A*0201) |
ELISA, multimer staining, cytotoxicity assay |
(NA) |
U11, U54 |
|
Nastke et al. (51) |
Computer-based epitope prediction (DRB1*0101) |
Cytokine bead assay, intracellular cytokine secretion (ICS), ELISpot, HLA-peptide tetramer staining |
U11, U14, U38, U48, U54, U47 |
(NA) |
|
Gerdemann et al. (40) |
CMV homolog selection |
ELISpot, ICS, cytotoxicity assay |
(NA) |
U11, U14, U54, U71, U90 |
|
Iampietro et al. (115) |
CMV homolog selection |
ICS, ELISA, cytotoxicity assay |
(NA) |
U54 |
|
Becerra-Artiles et al. (107) |
Selection by antigenic gel fractions of HHV-6B proteins followed by computer-based epitope prediction (DRB1*0101) |
ELISA, ELISpot, mass spectrometry, SDS-PAGE, fluorescence-polarization HLA peptide-binding competition assay |
U11, U14, U31, U39, U41, U48, U54, U57, U90, U100 |
(NA) |
|
Halawi et al. (105) |
CMV homolog selection |
ICS, ELISpot, ELISA |
(NA) |
U11, U90 |
|
Martin et al. (109) |
Computer-based epitope prediction (HLA-B*0801) |
ELISA, ELISpot, cytotoxicity assay, HLA-peptide multimer staining |
(NA) |
U3, U7, U26, U29, U31, U38, U41, U42, U53, U59, U64, U72, U79, U84, U86, B4 |